The North American pharmaceutical excipient market is estimated to grow at a CAGR of 7.9% during the forecast period. The increasing demand for pharmaceutical and biopharmaceutical drugs in the region significantly drives the growth of the market. Along with this, pharmaceutical patented drug approval of biosimilar is also expected to expand the market during the forecast period.
To Request a Free Sample of our North American Pharmaceutical Excipient Market: https://www.omrglobal.com/request-sample/north-american-pharmaceutical-excipient-market
The US FDA started approving biosimilars in March 2010. The cost of biosimilars is 20-40% less in the US, which provides an ample opportunity for the growth of the biosimilar industry and hence drives the growth of their excipients.
There is a substantial overall economic impact of the biopharmaceutical industry on the US economy. According to the International Trade Administration, the industry accounted for more than $1.3 trillion in economic output, representing 4% of total US output in 2015. The economic impact includes around $558 billion in revenue from the biopharmaceutical industry.
(Get 15% Discount on Buying this Report)
A full Report of North American Pharmaceutical Excipient Market is Available at: https://www.omrglobal.com/industry-reports/north-american-pharmaceutical-excipient-market
An exceptional growth for biopharmaceutical innovation has been noticed in 2015. The US FDA approved 56 new medicines, that included 45 new medicines approved by the Center for Drug Evaluation and Research (CDER)—the highest number of approvals in almost two decades. The US biopharmaceutical research sector has been involved in the development of new medicines, and it continues to drive biopharmaceutical innovation for patients in the near future.
Market Coverage
- Market number available for – 2018-2025
- Base year- 2018
- Forecast period- 2019-2025
- Segment Covered- By Product and By Formulation Type
- Regions Covered- North America
- Competitive Landscape- Colorcon Inc., Merck KGaA, Colorcon Inc., Innophos Holdings, Inc., Lubrizol Corp., and Archer Daniels Midland Co.
Key questions addressed by the report
- What is the market growth rate?
- Which segment/region dominates the market in the base year?
- Which segment/region will project the fastest growth in the market?
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
North American Pharmaceutical Excipient Market- Segmentation
By Products
- Solubilizers & Surfactants/Emulsifiers
- Polyols
- Carbohydrates
- Specialty Excipients
By Formulations
- Oral Formulations
- Topical Formulations
- Parenteral Formulations
- Other Formulations
North American Pharmaceutical Excipient Market– Segment by Region
· US
· Canada
Company Profiles
- ABITEC Corp.
- Overview
- ABITEC Corp. in North America
- ABITEC Corp. in Pharmaceutical Excipient Landscape
- Recent Developments
- Archer Daniels Midland Co
- BASF SE
- Colorcon, Inc.
- Innophos Holdings, Inc.
- Lubrizol Corp.
- Merck KGaA
- Sigachi Industries Pvt. Ltd.
- Spectrum Chemical Manufacturing Corp.
- SPI Pharma Inc.
Reasons to buy from us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
